Ferrous Sulfate Anhydrous

證據等級: L5

預測適應症: 10 個

Ferrous Sulfate Anhydrous: From Iron-Deficiency Anaemia to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia

One-Sentence Summary

Ferrous sulfate anhydrous (DrugBank DB13257) is conventionally used to treat iron-deficiency anaemia, though this evidence pack contains no documented original indication or mechanism-of-action data. The TxGNN model’s top prediction is vitamin B12- and folate-independent constitutional megaloblastic anemia, but this is currently supported by zero clinical trials and zero publications, and the model’s own mechanistic annotation flags the score as likely reflecting semantic similarity (“anemia”) rather than a genuine pharmacological link.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (`original_indications` is empty; drug is not registered in Australia). Ferrous sulfate is conventionally indicated for iron-deficiency anaemia, but this is background knowledge, not sourced from the pack.
Predicted New Indication	Vitamin B12- and folate-independent constitutional megaloblastic anemia
TxGNN Prediction Score	99.78%
Evidence Level	L5 (model prediction only, no supporting studies)
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available for ferrous sulfate anhydrous in this evidence pack (data gap DG002, severity: High). Based on general pharmacology, ferrous sulfate corrects iron deficiency by replenishing substrate for haemoglobin synthesis — a mechanism specific to microcytic, iron-deficient anaemias.

The predicted indication, however, is a constitutional (typically genetic) megaloblastic anaemia that is explicitly independent of vitamin B12 and folate — and by extension, unrelated to iron status. Megaloblastic anaemias of this type arise from defects in DNA synthesis (e.g., thiamine-responsive megaloblastic anaemia), not from a lack of iron. Supplementing iron would not correct this underlying defect.

The evidence pack’s own repurposing rationale for this candidate acknowledges this mismatch directly: the high TxGNN score likely reflects the model associating the two conditions through the shared word “anemia” in the knowledge graph, rather than a real shared mechanism. Notably, a lower-ranked candidate in this same pack — Plummer-Vinson syndrome (rank 2, L4/S1) — has a much stronger mechanistic basis, since iron-deficiency anaemia is the textbook aetiology of that condition and iron repletion is standard treatment. That candidate currently lacks trial/literature evidence in this pack (a data gap, not a mechanistic gap) and may warrant separate follow-up.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Australia Market Information

Ferrous sulfate anhydrous currently has no ARTG entries — market status is “Not marketed” with 0 recorded licences in this evidence pack.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication lacks both clinical and literature support, and the model’s own mechanistic annotation identifies the prediction as a probable knowledge-graph artefact (semantic overlap on “anemia”) rather than a biologically plausible mechanism. Combined with the drug’s non-marketed status in Australia and missing MOA/safety data, this candidate does not meet the threshold to proceed.

To proceed, the following is needed:

Confirmed original indication and mechanism-of-action data for ferrous sulfate anhydrous (DG002)
TGA/PI-sourced warnings and contraindications (DG001 — currently blocking safety review)
If pursuing an iron-related repurposing angle, targeted evidence collection for Plummer-Vinson syndrome (rank 2) instead, given its stronger mechanistic rationale
Independent expert review before treating any candidate in this pack as more than a preliminary signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.